BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, BioXcel Therapeutics, Inc. has 31.31M shares outstanding.

As of June 30, 2026, BioXcel Therapeutics, Inc. maintains a current ratio of 0.21, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -90.47, indicating conservative leverage, while an interest coverage ratio of -2.60 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -259.62, reflecting losses generated across the asset base. The company generates approximately 20,950.73 in revenue per employee across its workforce of 31.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.70 indicates how many times BioXcel Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on September 7, 2026, BioXcel Therapeutics, Inc.'s stock has declined approximately 98.46% over the past 52 weeks. The 50-day moving average sits at 0.71, while the 200-day moving average is 1.15.

Over the twelve months ended June 30, 2026, BioXcel Therapeutics, Inc. generated 649,472.60 in revenue and converted that into -62.02M in net income, yielding earnings per share of -3.09. EBITDA reached -39.13M, while operating income came in at -39.15M.

As of June 30, 2026, BioXcel Therapeutics, Inc. holds 11.24M in cash and equivalents against 91.43M in total debt, resulting in a net debt position of 80.19M. Total book value stands at -101.06M, with working capital of -94.93M providing operational flexibility.

BioXcel Therapeutics, Inc. produced -44.56M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -44.56M - equivalent to -2.22 per share.

Over the twelve months ended June 30, 2026, BioXcel Therapeutics, Inc. posted a gross margin of 53.10, reflecting its pricing power and cost economics. The operating margin of -6,028.57 and net profit margin of -9,549.87 provide insight into operational efficiency.

BioXcel Therapeutics, Inc.'s most recent stock split took place on February 10, 2025 with a 16:1 split ratio.